Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Bought by Quantbot Technologies LP

Quantbot Technologies LP raised its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 230.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 72,351 shares of the life sciences company's stock after acquiring an additional 50,459 shares during the quarter. Quantbot Technologies LP owned approximately 0.09% of Integra LifeSciences worth $1,315,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CWM LLC raised its holdings in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after acquiring an additional 425 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock worth $26,000 after purchasing an additional 444 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Integra LifeSciences by 7.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company's stock valued at $421,000 after buying an additional 1,010 shares during the last quarter. KBC Group NV grew its stake in shares of Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock valued at $52,000 after buying an additional 1,120 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Integra LifeSciences by 58.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company's stock worth $136,000 after buying an additional 1,711 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock traded up $0.04 on Friday, hitting $24.58. The stock had a trading volume of 249,836 shares, compared to its average volume of 1,153,843. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -273.11, a price-to-earnings-growth ratio of 0.84 and a beta of 1.08. The business's 50 day moving average is $20.77 and its two-hundred day moving average is $23.98. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same period last year, the firm earned $0.76 earnings per share. Integra LifeSciences's revenue was down .4% compared to the same quarter last year. Analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

IART has been the subject of a number of recent analyst reports. Truist Financial decreased their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Bank of America dropped their price objective on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research note on Monday, October 7th. Finally, Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.